# US 9,517,262 B2 · Vaccine injection, preparation method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,517,262 B2
- Document ID: US9517262B2
- Status: Granted
- Kind: B2
- Application number: 14/004,786
- Filed: 2011-04-08
- Published: 2014-01-02
- Granted: 2016-12-13
- Earliest claimed: 2011-03-16
- Assignees: China 302 Military Hospital of Pla; Jiabo Wang; Xiaohe Xiao; Zhewei Wang; Cheng Jin; Qi Li
- Applicants: Jiabo Wang; Xiaohe Xiao; Zhewei Wang; Cheng Jin; Qi Li
- Inventors: Jiabo Wang; Xiaohe Xiao; Zhewei Wang; Cheng Jin; Qi Li
- Web page: https://patentgrep.com/patent/US9517262B2

## CPC

- A61K 39/29: Hepatitis virus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 39/0275: {Salmonella}
- A61K 39/0291: {Yersinia}
- A61K 39/05: {Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium {(Mycobacterium A61K39/04)}
- A61K 39/07: Bacillus
- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61K 39/098: {Brucella}
- A61K 39/099: {Bordetella}
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/165: Mumps or measles virus
- A61K 39/20: Rubella virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides a vaccine injection, which includes a vaccine and a Traditional Chinese medicinal adjuvant in a mass ratio of 1:0.5-1:10, or a vaccine, a Traditional Chinese medicinal adjuvant and an aluminum adjuvant in a mass ratio of 1:0.5:2.5-1:10:20. The vaccine injection is in the form of powders, and the size of the powders is between 10 and 120 micrometers. The vaccine injection of the present invention is particularly suitable for the needle free injection technology. The invention also provides a preparation method for the vaccine injection.

## Claims

### Claim 1

A vaccine injection consisting of a vaccine, a Traditional Chinese medicinal adjuvant and an aluminum adjuvant in a mass ratio of 1:0.5:0.8-1:10:20, wherein the vaccine injection is in a form of a powder and the size of the powder is between 10-120 micrometers, wherein said vaccine is mumps vaccine, said Chinese medicinal adjuvant is astragalus polysaccharide, and
wherein said vaccine injection is obtained by the following preparation steps:
preparing an aluminum adsorption column with aluminum hydroxide as a supporter, flowing a solution of said vaccine and a solution of said Traditional Chinese medicinal adjuvant through said aluminum adsorption column,
drying said aluminum adsorption column, and
collecting powders with particle sizes between 10-120 micrometers, to obtain the vaccine injection.

### Claim 2 (depends on 1)

The vaccine injection of claim 1 wherein the vaccine injection is suitable for administration by needle-free injection.

### Claim 3 (depends on 1)

The vaccine injection of claim 1, wherein the step of flowing the solution of the vaccine and the solution of the Traditional Chinese medicinal adjuvant through the aluminum adsorption column comprises: flowing the solution of the vaccine through the aluminum adsorption column, and then flowing the solution of the Traditional Chinese medicinal adjuvant through the aluminum adsorption column.

### Claim 4 (depends on 1)

The vaccine injection of claim 1, wherein the step of flowing the solution of the vaccine and the solution of the Traditional Chinese medicinal adjuvant through the aluminum adsorption column comprises: flowing the solution of the Traditional Chinese medicinal adjuvant through the aluminum adsorption column, and then flowing the solution of the vaccine through the aluminum adsorption column.

### Claim 5 (depends on 1)

The vaccine injection of claim 1, wherein the step of flowing the solution of the vaccine and the solution of the Traditional Chinese medicinal adjuvant through the aluminum adsorption column comprises: mixing the solution of vaccine and the solution of the Traditional Chinese medicinal adjuvant together, and then flowing the mixed solution through the aluminum adsorption column.

### Claim 6 (depends on 1)

The vaccine injection of claim 1, wherein said vaccine, said Traditional Chinese medicinal adjuvant and said aluminum adjuvant are present in a mass ratio of 1:1:5-1:1:10.

### Claim 7 (depends on 1)

The vaccine injection of claim 1, wherein the size of the powder is between 30-70 micrometers.

### Claim 8 (depends on 6)

The vaccine injection of claim 6, wherein the size of the powder is between 30-70 micrometers.